

Study Show Diabetic & Weigh Loss Drug May Protect

Against Alzheimer's: Hawaii Memory Disorders Ctr &

Alzheimer's Research Unit - 1 of 70 US Centers


Investigating Semaglutide GLP-1 RA (Glucagon Like

Peptide 1-Receptor Agonist) in Alzheimer's since 2021

HONOLULU July 31, 2024 - Weight loss and diabetic drug similar to Ozempic appeared to slow cognitive decline in patients with mild Alzheimer's disease, new research presented this week in Philadelphia at the Alzheimer's Association International Conference. Hawaii Memory Center and Alzheimer's research Unit is part of Novo Nordisk's phase 3 clinical trials that will compare semaglutide to a placebo in more than 3,000 patients with mild cognitive impairment or early-stage Alzheimer's disease. About a dozen Hawaii patients are currently in these active on-going clinical trials.

Is Alzheimer's an Insulin Signaling

Problem? According to <u>Evaluate</u>, study testing the hypothesis that neurodegeneration is linked to low insulin and insulin resistance, and thus that a GLP-1 analogue diabetes drug like Novo's Victoza could improve cognitive



function. A correlation between blood glucose levels and rate of cognitive decline can be seen even without clinical diabetes, some have suggested, but type 2 diabetes almost doubles the risk of developing Alzheimer's and is associated with accelerated cognitive decline in people with mild cognitive impairment.

Semaglutide has specifically been shown to reduce measures of neuro-inflammation which may affect cognition and function in a post-hoc analysis of data from three large cardiovascular outcomes trials conducted by Novo Nordisk (LEADER, SUSTAIN 6 and PIONEER 6), which included 15,820 patients with type 2 diabetes with median follow-up of 3.6 years. The rate of developing dementia was statistically significantly reduced by 53% in favour of GLP-1.

Randomized Double-blind Placebo-controlled Clinical Trial Investigating the Effect and Safety of Oral Semaglutide in Subjects with Early Alzheimer's Disease (EVOKE) (NIH Info)



"Thanks to the support of our community, our team of neurologists, dementia specialists and investigators and dedicated research staff at the <u>Memory Disorders Center</u> & <u>Alzheimer's Research Unit</u> at Hawaii Pacific Neuroscience, in Honolulu cannot be more proud of the work we do here in Hawaii to contribute to the worldwide effort to meet unmet needs in this exciting field in Alzheimer's and Neurodegeneration", says <u>Kore Liow, MD</u>, Principal Investigator and Neurologist, Hawaii Pacific Neuroscience. info@HawaiiNeuroscience.com or Alzheimer's Research Unit Hotline (808) 564-6141 or <u>NIH Info</u>